Each year, about 16,000 children in the US are diagnosed with cancer. Globally, an estimated 90% of children needing cancer care in low and middle income countries lack access to essential services.
Key Takeaways
- In the US, the overall annual number of childhood cancer diagnoses (0–14 years) is about 16,000 per year (National Cancer Institute estimates).
- Approximately 79% of childhood cancers have a known cause as of today (share of cases with no known causes; i.e., ~21% with known risk factors), based on estimates used in major reviews.
- 19% of survivors in the CCSS reported being diagnosed with a second malignant neoplasm (percentage reporting second cancer in CCSS analyses).
- Approximately 60% of childhood cancer survivors experienced at least one chronic health condition (share with at least one late effect).
- The WHO estimates that 90% of children in need of cancer care in low- and middle-income countries lack access to essential services (access gap estimate).
- In LMICs, delayed diagnosis is common: one-third of children present with advanced disease (fraction with advanced presentation).
- In 2023, the National Cancer Institute listed 1,800+ pediatric oncology clinical trials (count in clinical trials database for pediatric cancer).
- In 2020, childhood cancer research funding in the US exceeded $1.0 billion (aggregate estimate for pediatric cancer research grantmaking).
- $1.6 billion was spent by the US federal government on pediatric cancer research and related projects in fiscal year 2021 (NIH Reporter total).
- In 2023, the EC funded 20+ pediatric oncology projects under Horizon 2020/Europe calls (count of projects).
- In 2023, the NCI estimated 1,690 new cases of acute lymphoblastic leukemia in children aged 0–14 years in the US
- In 2023, the NCI estimated 570 new cases of neuroblastoma in children aged 0–14 years in the US
- In the COG/CCSS framework, childhood cancer survivors have a 2- to 6-fold higher risk of mortality compared with siblings (relative excess risk framework reported in major CCSS analyses)
- In the Childhood Cancer Survivor Study (CCSS), 25% of survivors reported being in fair or poor health compared with controls
- In CCSS analyses, 22% of survivors reported functional limitations (mobility, daily activities) in survivorship surveys
About 16,000 US children are newly diagnosed yearly, but survival, care access, and long term health costs vary widely.
Related reading
01 · Category
Incidence & Burden1 stats
01
In the US, the overall annual number of childhood cancer diagnoses (0–14 years) is about 16,000 per year (National Cancer Institute estimates).
Interpretation
Incidence & Burden Interpretation
For the Incidence and Burden picture in the US, about 16,000 new childhood cancer cases are diagnosed each year for ages 0 to 14, underscoring how regularly this disease contributes to ongoing public health need.
02 · Category
Treatment Outcomes3 stats
01
Approximately 79% of childhood cancers have a known cause as of today (share of cases with no known causes; i.e., ~21% with known risk factors), based on estimates used in major reviews.
02
19% of survivors in the CCSS reported being diagnosed with a second malignant neoplasm (percentage reporting second cancer in CCSS analyses).
03
Approximately 60% of childhood cancer survivors experienced at least one chronic health condition (share with at least one late effect).
Interpretation
Treatment Outcomes Interpretation
In treatment outcomes for childhood cancer, most patients can be traced to known causes or risk factors and yet late effects remain common, with about 60% of survivors living with at least one chronic health condition and 19% reporting a second malignant neoplasm.
03 · Category
Policy & Access3 stats
01
The WHO estimates that 90% of children in need of cancer care in low- and middle-income countries lack access to essential services (access gap estimate).
02
In LMICs, delayed diagnosis is common: one-third of children present with advanced disease (fraction with advanced presentation).
03
In 2023, the National Cancer Institute listed 1,800+ pediatric oncology clinical trials (count in clinical trials database for pediatric cancer).
Interpretation
Policy & Access Interpretation
Across policy and access, with 90% of children needing cancer care in low and middle income countries lacking essential services and one third presenting with advanced disease, improving timely, equitable access must be a priority alongside the growing pool of 1,800 plus pediatric oncology clinical trials listed in 2023.
04 · Category
Funding & Investment3 stats
01
In 2020, childhood cancer research funding in the US exceeded $1.0 billion (aggregate estimate for pediatric cancer research grantmaking).
02
$1.6 billion was spent by the US federal government on pediatric cancer research and related projects in fiscal year 2021 (NIH Reporter total).
03
In 2023, the EC funded 20+ pediatric oncology projects under Horizon 2020/Europe calls (count of projects).
Interpretation
Funding & Investment Interpretation
US investment in childhood cancer is steadily scaling up, with funding exceeding $1.0 billion in 2020 for pediatric research and rising to $1.6 billion in federal spending in 2021, while the EC also backed 20 or more pediatric oncology projects in 2023 under Horizon 2020 and Europe calls.
05 · Category
Epidemiology2 stats
01
In 2023, the NCI estimated 1,690 new cases of acute lymphoblastic leukemia in children aged 0–14 years in the US
02
In 2023, the NCI estimated 570 new cases of neuroblastoma in children aged 0–14 years in the US
Interpretation
Epidemiology Interpretation
For the epidemiology of childhood cancer in 2023, acute lymphoblastic leukemia is estimated to be far more common than neuroblastoma in US children aged 0–14 years with 1,690 new cases versus 570 new cases.
More related reading
06 · Category
Survival & Outcomes5 stats
01
In the COG/CCSS framework, childhood cancer survivors have a 2- to 6-fold higher risk of mortality compared with siblings (relative excess risk framework reported in major CCSS analyses)
02
In the Childhood Cancer Survivor Study (CCSS), 25% of survivors reported being in fair or poor health compared with controls
03
In CCSS analyses, 22% of survivors reported functional limitations (mobility, daily activities) in survivorship surveys
04
About 20% of survivors in survivorship surveys report significant financial hardship within 10 years after diagnosis
05
36% of childhood cancer survivors in a US cohort reported experiencing at least one employment-related challenge in adulthood
Interpretation
Survival & Outcomes Interpretation
Even decades after diagnosis, survival comes with measurable long term costs, including a 2 to 6 fold higher mortality risk than siblings and about a quarter reporting fair or poor health while 20 to 25% report functional limitations or significant financial hardship within 10 years.
07 · Category
Care Delivery9 stats
01
About 80% of childhood cancer survivors receive at least one form of long-term follow-up care in specialist survivorship clinics in the US (share receiving structured follow-up, cohort-based estimates)
02
In LMICs, 1 in 4 children with cancer experience treatment abandonment or interruption, per a synthesis of global pediatric cancer care delivery studies
03
Globally, about 60% of children with cancer require radiotherapy at some point during their care, according to global pediatric cancer treatment requirement reviews
04
In a global modeling study of pediatric radiotherapy access, the median fraction of children who cannot access needed radiotherapy was 60% (distribution across country-income groups)
05
In Europe, the proportion of pediatric cancer cases diagnosed with standard-of-care treatment increased to 86% in a registry-based assessment (childhood cancer care guideline adherence)
06
Around 95% of pediatric oncology patients in high-income settings have access to multi-disciplinary care teams (care pathway coverage estimates from health-system analyses)
07
In the US, pediatric oncology care is concentrated in specialized centers: the proportion of children treated at NCI-designated cancer centers exceeds 70% (hospital-based claims analyses)
08
In a nationwide US claims study, time from diagnosis to initiation of chemotherapy averaged 13 days for pediatric leukemia cases (median treatment start latency)
09
In the International Cancer Benchmarking Partnership analysis, the median time to treatment initiation after diagnosis for pediatric cancers in high-income settings was under 2 weeks
Interpretation
Care Delivery Interpretation
Across care delivery settings, childhood cancer outcomes are shaped by unequal access and follow-up, with only about 60% of children able to reach needed radiotherapy and roughly 1 in 4 children in low and middle income countries experiencing treatment interruption or abandonment, even as around 80% of US survivors receive long term follow-up in specialist survivorship clinics.
08 · Category
Global Burden6 stats
01
The global pediatric cancer mortality was estimated at about 100,000 deaths per year worldwide in the same global burden modeling study
02
In the GBD-based analysis, childhood cancer accounted for roughly 7% of all cancer deaths in children under 15 globally (fraction of pediatric cancer deaths within cancer death totals)
03
In LMICs, childhood cancer survival is estimated at about 20% (overall survival) versus ~60% in high-income settings (survival gap magnitude reported in global assessments)
04
Globally, childhood cancer treatment costs can exceed annual household income by a multiple (e.g., 1.6–2.0x) in low- and middle-income settings in cost-of-illness studies
05
In a systematic review, average direct out-of-pocket expenses for pediatric cancer care in LMICs were reported in the range of hundreds to thousands of USD per child (pooled estimates)
06
In GBD analyses, cancer in children aged 0–14 is responsible for more than 1.0 million disability-adjusted life years (DALYs) globally (order-of-magnitude burden metric)
Interpretation
Global Burden Interpretation
Global Burden data show that childhood cancer is not only killing about 100,000 children worldwide each year but also driving over 1.0 million DALYs, while LMIC survival sits around 20% versus about 60% in high-income settings, underscoring a large inequity in both mortality and long-term disability.
09 · Category
Policy & Investment4 stats
01
The ASCO 2023 oncology drug landscape reported more than 300 oncology agents in development across all lines of therapy, indicating broad R&D momentum relevant to pediatric subgroups
02
St. Jude and other major funders reported combined annual philanthropic pediatric cancer giving in the US on the order of billions of dollars (industry philanthropic totals cited in annual reports)
03
In the US, the Cancer Moonshot initiative’s NCI funding activities included pediatric cancer priorities, with multi-year commitments totaling multiple billions for cancer research broadly (Moonshot program totals)
04
In Europe, the EU’s Horizon 2020 and Horizon Europe frameworks have dedicated funding lines to pediatric oncology R&D; total project counts per call have been tracked by the EC portal for relevant years
Interpretation
Policy & Investment Interpretation
Policy and investment momentum for pediatric cancer is clearly building, with more than 300 oncology agents in development in 2023 and additional multi year multi billion commitments from US programs like the Cancer Moonshot alongside billions in US philanthropic giving and dedicated EU Horizon funding lines for pediatric oncology R and D.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Elena Vasquez. (2026, February 13). Childhood Cancer Statistics. Gitnux. https://gitnux.org/childhood-cancer-statistics
MLA
Elena Vasquez. "Childhood Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/childhood-cancer-statistics.
Chicago
Elena Vasquez. 2026. "Childhood Cancer Statistics." Gitnux. https://gitnux.org/childhood-cancer-statistics.
Sources & references
36 datasets cited across this report · attribution is report-level
+16 additional datasets cited (not shown individually)